1. The antibiotic reality
The antibiotic market is a >$30 billion market worldwide
The antibiotic pipeline is as empty as it has been since
the discovery of antibiotics
(97% of antibiotics in development are analogs of existing drugs)
Antibiotic resistance has emerged as a major challenge
in public and personal health
The search for single “blockbuster” broad-spectrum
antibiotics is both medically and ecologically foolish

2. The antibiotic crisis: MRSA

3. Origin is committed to the design of effective
The new antibiotic landscape
The search for single “blockbuster” broad-spectrum antibiotics is medically, ecologically and financially untenable.
Origin is committed to the design of effective
narrow spectrum antimicrobials that:
Specifically target pathogenic organisms
Reduce the emergence of resistance
Leverage developments in diagnostics
and personalized medicine

4. Bacteriocin Diversity
Bacteriocins
May be universally
present in Bacteria,
certainly prevalent
E. coli - colicins
P. aeruginosa - pyocin
B. subtilis - subtilin
S. epidermis - epidermin
L. brevis - brevicin
Archaeacins
Universally present

5. “…pitted against microbial genes we have mainly our wits
“…pitted against microbial genes we have mainly our wits.” Joshua Lederberg
Our leads derive from a family of naturally-occurring antimicrobials, the bacteriocins Ubiquitous Specific and targetable Nontoxic to vertebrates Modifiable and patentable Ia E9

6. 3 billion years of R&D Conventional antibiotics
Dr. Robert Dorit or Dr. Margaret Riley
For additional information, contact:
Yr 15-20
Discovery
Preclinical
Animal Trials
Phase I
Phase II
Phase III
FDA
Post
Market
Yr 0
Yr 7
Conventional antibiotics
Discovery
Preclinical
Animal Trials
Phase I
Phase II
Phase III
FDA
Post
Market
Yr 0
Yr 2
The lead to bedside pipeline